EPHA2 and neoplasm: While treatment with ephrinA1 (Fc- and His-tagged) increased the tumor-suppressive EphA2-pY588 in these cells, as expected upon ligand-mediated receptor activation, this phosphorylation was not altered by ephrinA5 (Fc- and His-tagged) in OVCAR3 and remained lower in OVCAR4, compared to the respective ephrinA1 (Fc- and His-tagged) treated cells (Fig. 3A, B).